Alzheimer's Clinical Trials in Syracuse
View 15 new treatments for Alzheimer's in Syracuse, NY near me. Every day, Power helps hundreds of Alzheimer's patients connect with leading medical research.Masupirdine for Agitation in Alzheimer's Disease
Suven Life Sciences Clinic, East Syracuse + 1 more
This trial will test a medication called masupirdine, which participants will take regularly. It targets people with Alzheimer's disease who are experiencing agitation. The study aims to see if masupirdine can help reduce agitation and ensure it is safe and well-tolerated. Masupirdine has been previously evaluated in patients with moderate Alzheimer's disease and was found to be generally safe and well-tolerated.Show More
KarXT for Psychosis in Alzheimer's Disease
Karuna Clinic, Syracuse + 1 more
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.Show More
Donanemab for Early Alzheimer's Disease
Eli Lilly Clinic, East Syracuse + 3 more
This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.Show More
Long-Term Safety of Simufilam for Alzheimer's Disease
Cassava Sciences Clinic, East Syracuse + 1 more
The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.Show More
No Placebo Trial
Donanemab for Alzheimer's Disease
Eli Lilly Clinic, East Syracuse + 3 more
This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.Show More
Semaglutide for Early Alzheimer's Disease
Novo Nordisk Clinic, Syracuse + 2 more
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.Show More
[18F]PI-2620 PET Imaging for Alzheimer's Disease
Life Molecular Imaging Clinic, East Syracuse + 1 more
This trial tests a brain scan that uses a special substance to detect harmful proteins in people with Alzheimer's disease.
No Placebo Trial
Benfotiamine for Alzheimer's Disease
Research Clinic, Syracuse + 1 more
The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.Show More
AL002 for Alzheimer's Disease
Alector Clinic, Syracuse + 1 more
This trial tests AL002, a drug for early Alzheimer's disease, in people who were part of an earlier study. It aims to check if AL002 is safe and effective over time.Show More
No Placebo Trial
JNJ-64042056 for Alzheimer's Disease
Janssen Clinic, East Syracuse + 1 more
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.Show More
Frequently Asked Questions
How much do alzheimer's clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.
Do I need to be insured to participate in a medical study?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
How do alzheimer's clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across alzheimers trials in Syracuse, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for alzheimers patients is 6 Months.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.
Where in Syracuse is research being conducted for alzheimer's?
SUNY Upstate Medical University is a prominent hospital in Syracuse conducting Alzheimer's clinical trials, with approximately 5 trials as of 2024. Additionally, Velocity Clinical Research is actively involved in the eastern area of Syracuse, hosting around 5 trials.
What promising new drugs are being tested?
In Syracuse, Alzheimer's research is focusing on treatments like Monoclonal Antibodies and Glucagon-like peptide-1 receptor agonists. Notable drugs being studied include Donanemab, AL002, and Semaglutide.